CYP19A1 and breast cancer: The impact of targeting BCL-2 in ER+ breast cancer has been evaluated in clinical phase I and II studies (NCT03900884 & NCT03584009) investigating BCL-2 inhibition by Venetoclax in combination with aromatase/cyclin-dependent kinase inhibitors and hormone therapy, respectively [50].